Author, year | Study Design | No. of Patients (Male/Female) | Age (y) Mean ± SD or Range | Baseline IGF-1 level (μg*L−1) Mean ± SD | Previous Treatment (n) | Mean or Median dosages of SAs and PEG | Outcomes | Duration of SAs and PEG treatment | Duration of Study/months |
---|---|---|---|---|---|---|---|---|---|
Jorgensen, 2005 [29] | Non-controlled, Prospective | 11 (7/4) | 23–71 | 269 ± 29 | Surgery (9), Radiotherapy (5), SAs(10) | Octreotide: 30 mg/2–4 weeks PEG: 15 mg/day | IGF-1 levels, GH levels, FPG, FPI, 2-h plasma glucose value | Octreotide: not reported PEG: 12 weeks | 8 |
Neggers, 2008 [23] | Placebo-controlled, Crossover, Prospective | 20 (11/9) | 39–74 | 187.5 ± 35 | Both surgery and radiotherapy (6), Surgery (15), Primary medical therapy (5) | SAs: Not reported PEG: 40 mg/week | IGF-1 levels, glycosylated hemoglobin, FPG, TC, low-density lipoprotein, TELETs, Patient-Assessed Acromegaly Symptom Questionnaire, Acromegaly Quality of Life Questionnaire | SAs: 32 weeks PEG: 32 weeks | 9 |
Trainer, 2009 [22] | RCT | 84 (44/40) | 24–70 | 626.477 ± 49 | Surgery, Octreotide | Octreotide: 30 mg/28 days PEG: 15 mg/day | IGF-1 levels, acromegaly signs and symptoms, The Acromegaly Quality of Life Questionnaire, Euro Quality of Life-5 Dimensions Questionnaires, Glycaemic control, adverse event | Octreotide: 44 weeks PEG: 40 weeks | 10 |
Madsen, 2011 [24] | RCT | 18 (7/11) | 54.2 ± 10.9 | Not reported | Surgery (14), Radiotherapy (2), SAs (18) | Octreotide: 6.7-20 mg/28 days Lanreotide: 24-60 mg/28 days PEG: 52.5 mg/week | IGF-1 levels, GH levels, 2-h glucose, FPG, FPI, Insulin sensitivity and substrate metabolism, Quality of life, Adverse effects | SAs: 24 weeks PEG: 24 weeks | 6 |
Van der Lely, 2011 [27] | Non-controlled, Prospective | 57 (29/28) | 51.6 ± 12.7 | Not reported | Surgery (38), Radiotherapy (18), SAs (44), Lanreotide (24), Octreotide (20), PEG (13) | Lanreotide: 120 mg/months PEG: 60 mg/week | IGF-1 levels, acromegaly symptoms, Acromegaly Quality of Life Questionnaire, glucose tolerance, electrocardiograms, hepatic function tests, standard hematological, biochemical laboratory tests | Lanreotide: 44 weeks PEG: 28 weeks | 7 |
Colao, 2019 [25] | Longitudinal, Comparative, Prospective | 31 (14/17) | 44.6 ± 10.5 | 643 | SAs | Lanreotide: 40 mg/28 days PEG: 70 mg/week | Biochemical control rate, Acromegaly-related clinical signs and symptoms, Health-related quality of life, Safety | SAs: 8 months PEG: 4 months | 8 |
Muhammad, 2018 [26] | Follow-up, Prospective | 30 | 53 | Not reported | Surgery, Radiotherapy, SAs | Pasireotide: 60 mg/28dyas PEG: 64 mg/week | Percentage of responders, Percentage of patients who stop PEG after 48 weeks, Percentage cumulative PEG dose reduction, Safety | Pasireotide: 36 weeks PEG: 48 weeks | 12 |
Auriemma, 2016 [28] | Non-controlled, Prospective | 36 (14/22) | 52.3 ± 10.2 | 703.6 ± 258.3 | Surgery, Radiotherapy, Octreotide (11), Lanreotide (25) | Octreotide: 30 mg/28 days Lanreotide: 120 mg/28 days PEG: 100 mg/week | IGF-1levels, cardiovascular parameters, glucose and lipid levels, tumor volume | SAs: 114 months PEG: 78 months | 78 |
Urbani, 2013 [2] | Non-controlled, Prospective | 31 (15/16) | 46.47 ± 2.33 | Not reported | SAs (31) | Octreotide: 27.50 mg/28 days Lanreotide: 120 mg/28 days PEG: 16.9 mg/day | IGF-1 index, GH, Glucose metabolism | SAs: not reported PEG: not reported | 48 |